Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patients

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Cung, Heidi ^a   Aragon, Mario J ^a   Zychowski, Katherine ^a   Anderson, Joe R ^a   Nawarskas, James ^a   Roldan, Carlos ^b   Sood, Akshay ^b   Qualls, Clifford ^b   Campen, Matthew J ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Coronary artery disease; Endothelia; Inflammatory; Serum

Indexed keywords

C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN; IL8 PROTEIN, HUMAN;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; ASSAY; BLOOD SAMPLING; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; ENDOTHELIAL CELL BIOSENSOR ASSAY; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE ISOLATION; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MALE; UPREGULATION; ADOLESCENT; AGE; AGED; BIOASSAY; BLOOD; BODY MASS; CASE CONTROL STUDY; COHORT ANALYSIS; CORONARY BLOOD VESSEL; DEMOGRAPHY; GENETIC PROCEDURES; LUMINESCENCE; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; PROCEDURES; SEXUAL DEVELOPMENT; STATISTICAL MODEL; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL ASSAY; BIOSENSING TECHNIQUES; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; CORONARY VESSELS; DEMOGRAPHY; ENDOTHELIAL CELLS; FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; LINEAR MODELS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SEX CHARACTERISTICS; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84925827527     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0457-5     Document Type: Article

References (28)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26. doi:10.1056/NEJM199901143400207.
2. Corbi G, Bianco A, Turchiarelli V, Cellurale M, Fatica F, Daniele A, et al. Potential Mechanisms Linking Atherosclerosis and Increased Cardiovascular Risk in COPD: Focus On Sirtuins. Int J Mol Sci. 2013;14:12696-713. doi:10.3390/ijms140612696.
3. Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186:11-6. doi:10.1164/rccm.201203-0455PP.
4. Lahousse L, van den Bouwhuijsen QJ, Loth DW, Joos GF, Hofman A, Witteman JC, et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med. 2013;187:58-64. doi:10.1164/rccm.201206-1046OC.
5. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2013;25:147-51. doi:10.1097/MEG.0b013e32835a58b1.
6. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045-50. doi:10.1161/01.ATV.0000160613.57985.18.
7. Barve S, Joshi-Barve S, Song Z, Hill D, Hote P, Deaciuc I, et al. Interactions of cytokines, S-Adenosylmethionine, and S-Adenosylhomocysteine in alcohol-induced liver disease and immune suppression. J Gastroenterol Hepatol. 2006;21 Suppl 3:S38-42. doi:10.1111/j.1440-1746.2006.04590.x.
8. McClain CJ, Hill DB, Song Z, Chawla R, Watson WH, Chen T, et al. S-Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol. 2002;27:185-92.
9. Liang YJ, Shyu KG, Wang BW, Lai LP. C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol. 2006;40:412-20. doi:10.1016/j.yjmcc.2005.12.008.
10. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, et al. C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis. 2006;185:39-46. doi:10.1016/j.atherosclerosis.2005.01.057.
11. Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, et al. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci U S A. 1991;88:6523-7.
12. Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62:397-408. doi:10.1016/j.jacc.2013.05.016.
13. Channell MM, Paffett ML, Devlin RB, Madden MC, Campen MJ. Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: evidence from a novel translational in vitro model. Toxicol Sci. 2012;127:179-86. doi:10.1093/toxsci/kfs084.
14. Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003;107:2342-7. doi:10.1161/01.CIR.0000066691.52789.BE.
15. Barbieri SS, Zacchi E, Amadio P, Gianellini S, Mussoni L, Weksler BB, et al. Cytokines present in smokers' serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc Res. 2011;90:475-83. doi:10.1093/cvr/cvr032.
16. Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG, et al. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol. 2013;166:246-8. doi:10.1016/j.ijcard.2012.09.027.
17. 3 exposure. Toxicol Sci. 2013;134:304-11. doi:10.1093/toxsci/kft107.
18. Campen M, Robertson S, Lund A, Lucero J, McDonald J. Engine exhaust particulate and gas phase contributions to vascular toxicity. Inhal Toxicol. 2014;26:353-60. doi:10.3109/08958378.2014.897776.
19. Heyward VH. Practical body composition assessment for children, adults, and older adults. Int J Sport Nutr. 1998;8:285-307.
20. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-20. doi:10.1056/NEJMoa1107477.
21. Emerging Risk Factors C, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499-506. doi:10.1001/jama.2012.6571.
22. Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. J Am Coll Cardiol. 2013;62:717-29. doi:10.1016/j.jacc.2013.02.098.
23. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007;99:1706-13. doi:10.1016/j.amjcard.2007.01.062.
24. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793-8.
25. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM, Investigators CS. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2:1934-40. doi:10.1111/j.1538-7836.2004.01017.x.
26. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-84.
27. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332-7. doi:10.1016/j.jacc.2005.06.088.
28. Solheim S, Pettersen AA, Arnesen H, Seljeflot I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost. 2006;96:660-4.